By Judy George
Source Medpagetoday
High-dose supplements of docosahexaenoic acid (DHA), an omega-3 fatty acid, penetrated the brain in both APOE4 carriers and non-carriers before dementia onset, the placebo-controlled PreventE4 trial showed.
The treatment did not influence hippocampal volume, said Hussein Yassine, MD, of the Keck School of Medicine at the University of Southern California in Los Angeles. However, increases in brain DHA in both the treatment and placebo arms were associated with better cognitive measures in APOE4 carriers, Yassine reported at the Clinical Trials on Alzheimer’s Diseaseopens in a new tab or window annual meeting in Madrid.
Read more https://www.medpagetoday.com/meetingcoverage/ctad/112713